Advertisement
BRKR vs TMO
Which Stock Would AI Choose? Bruker Corporation (BRKR) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- Both BRKR and TMO operate in the scientific instruments sector, serving life sciences and diagnostics, but TMO offers broader diversification across segments like analytical instruments and specialty diagnostics.
- In recent market activity, BRKR has shown stronger short-term momentum, rising about 21% over the past month compared to TMO's 12% gain.
- Year-to-date through mid-April 2026, BRKR is up approximately 13%, edging out TMO's 9% advance.
- TMO boasts a significantly larger market capitalization of around $195 billion versus BRKR's $6 billion, implying greater stability but slower percentage moves.
- Analyst price targets suggest more upside potential for TMO at about 23% above current levels, compared to 14% for BRKR.
- Recent developments include collaborations and orders boosting sentiment for both, with TMO approaching quarterly earnings.
Introduction
This stock comparison examines BRKR and TMO, two key players in the scientific instruments and life sciences sector. Traders and investors tracking healthcare and biotech equipment may find value here, as both companies benefit from demand in research tools, diagnostics, and biopharma applications. Amid sector rotation and macroeconomic shifts, understanding their relative performance, business drivers, and market positioning aids in evaluating opportunities in this resilient niche. Recent weeks have seen momentum shifts influenced by earnings previews, partnerships, and broader market trends in precision medicine.
BRKR Overview and Recent Performance
Bruker Corporation (BRKR) develops high-performance scientific instruments and solutions for molecular and cellular analysis, including mass spectrometry, NMR, and microscopy systems used in academia, pharma, and biotech. Trading around $41 per share with a market cap of $6.3 billion, its 52-week range spans $28.53 to $56.22. In recent weeks, BRKR shares have gained over 20% monthly and nearly 7% weekly, reflecting positive momentum from Q4 2025 earnings that beat revenue estimates at $977 million despite cautious 2026 guidance. Key influences include multi-year $500 million orders for MRI superconductors and collaborations like AFM IR with Imec, driving sentiment amid helium supply concerns and biopharma demand. Year-to-date gains stand at 13%, outperforming broader indices in volatile conditions.
TMO Overview and Recent Performance
Thermo Fisher Scientific Inc. (TMO) is a global leader in serving science, with segments in life sciences solutions, analytical instruments, specialty diagnostics, and lab products supporting research, healthcare, and industrial applications. At about $526 per share and a $195 billion market cap, its 52-week range is $385 to $644. Recent market activity shows TMO up 12% monthly and 5% weekly, buoyed by anticipation for Q1 2026 earnings on April 23, where EPS of $5.21 and $10.8 billion revenue are expected. Sentiment has improved via precision-health alliances and proteomics advancements, following Q4 beats. Year-to-date performance is up 9%, with recovery from earlier highs amid steady biopharma and diagnostics demand.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top 25 performers from over 350 AI trading bots that analyze thousands of tickers across stocks, ETFs, and crypto using machine learning for real-time signals. These virtual and brokerage agents employ diverse strategies like swing trading, scalping (5-60 minute timeframes), trend following, and sector-specific plays (e.g., semiconductors, industrials, energy). Standout stats include win rates of 55-88%, profit factors from 1.5 to 11.7, annualized returns ranging 25-120%, and profit-to-drawdown ratios up to 11, with average trade durations of 1-10 days. None currently highlight BRKR or TMO specifically, but bots adapt to market conditions. Traders can explore these high-potential options for copy trading insights tailored to current volatility.
Head-to-Head Comparison
BRKR focuses on specialized analytical tools like mass spectrometers and imaging, contrasting TMO's diversified model spanning consumables and services for scale advantages. Growth drivers overlap in biopharma R&D and diagnostics, but TMO benefits from broader healthcare exposure. Recent momentum favors BRKR with sharper gains, while TMO exhibits steadier trends. Risk factors include helium costs and supply chains for BRKR (smaller cap implies higher volatility) versus regulatory and reimbursement pressures for TMO. Sector ties to life sciences unite them, but market sentiment leans toward TMO's scale amid economic uncertainty, per analyst overweight ratings for both.
Tickeron AI Verdict
Tickeron’s AI currently leans toward TMO with higher probability for sustained outperformance, owing to its trend consistency, larger scale for resilience, upcoming earnings catalysts, and greater implied upside from analyst targets. While BRKR shows impressive short-term momentum, TMO's relative positioning in a stable sector offers probabilistic edge in the current environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BRKR is a Hold and TMO is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BRKR’s FA Score shows that 1 FA rating(s) are green whileTMO’s FA Score has 1 green FA rating(s).
- BRKR’s FA Score: 1 green, 4 red.
- TMO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BRKR’s TA Score shows that 5 TA indicator(s) are bullish while TMO’s TA Score has 3 bullish TA indicator(s).
- BRKR’s TA Score: 5 bullish, 5 bearish.
- TMO’s TA Score: 3 bullish, 7 bearish.
Price Growth
BRKR (@Medical/Nursing Services) experienced а -3.83% price change this week, while TMO (@Medical Specialties) price change was -0.73% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.39%. For the same industry, the average monthly price growth was +1.95%, and the average quarterly price growth was -16.80%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.27%. For the same industry, the average monthly price growth was +8.03%, and the average quarterly price growth was -5.20%.
Reported Earning Dates
BRKR is expected to report earnings on Aug 05, 2026.
TMO is expected to report earnings on Jul 29, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.39% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-0.27% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BRKR | TMO | BRKR / TMO | |
| Capitalization | 8.26B | 174B | 5% |
| EBITDA | 306M | 11.7B | 3% |
| Gain YTD | 15.286 | -18.922 | -81% |
| P/E Ratio | 74.88 | 25.80 | 290% |
| Revenue | 3.46B | 45.2B | 8% |
| Total Cash | 133M | 3.26B | 4% |
| Total Debt | 1.67B | 43.2B | 4% |
BRKR | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 65 | 77 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 43 Fair valued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 93 | |
SMR RATING 1..100 | 92 | 62 | |
PRICE GROWTH RATING 1..100 | 38 | 53 | |
P/E GROWTH RATING 1..100 | 5 | 47 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (12) in the Medical Specialties industry is in the same range as BRKR (43). This means that TMO’s stock grew similarly to BRKR’s over the last 12 months.
TMO's Profit vs Risk Rating (93) in the Medical Specialties industry is in the same range as BRKR (100). This means that TMO’s stock grew similarly to BRKR’s over the last 12 months.
TMO's SMR Rating (62) in the Medical Specialties industry is in the same range as BRKR (92). This means that TMO’s stock grew similarly to BRKR’s over the last 12 months.
BRKR's Price Growth Rating (38) in the Medical Specialties industry is in the same range as TMO (53). This means that BRKR’s stock grew similarly to TMO’s over the last 12 months.
BRKR's P/E Growth Rating (5) in the Medical Specialties industry is somewhat better than the same rating for TMO (47). This means that BRKR’s stock grew somewhat faster than TMO’s over the last 12 months.
| BRKR | TMO | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 69% | 4 days ago 55% |
| Stochastic ODDS (%) | 4 days ago 73% | 4 days ago 57% |
| Momentum ODDS (%) | 4 days ago 72% | 4 days ago 57% |
| MACD ODDS (%) | 4 days ago 78% | 4 days ago 62% |
| TrendWeek ODDS (%) | 4 days ago 72% | 4 days ago 61% |
| TrendMonth ODDS (%) | 4 days ago 73% | 4 days ago 61% |
| Advances ODDS (%) | 18 days ago 69% | 15 days ago 62% |
| Declines ODDS (%) | 8 days ago 72% | 4 days ago 63% |
| BollingerBands ODDS (%) | 4 days ago 69% | 4 days ago 55% |
| Aroon ODDS (%) | 4 days ago 68% | 4 days ago 63% |
Advertisement
BRKR and
Correlation & Price change
A.I.dvisor indicates that over the last year, BRKR has been closely correlated with A. These tickers have moved in lockstep 78% of the time. This A.I.-generated data suggests there is a high statistical probability that if BRKR jumps, then A could also see price increases.
| Ticker / NAME | Correlation To BRKR | 1D Price Change % | ||
|---|---|---|---|---|
| BRKR | 100% | -1.72% | ||
| A - BRKR | 78% Closely correlated | +0.22% | ||
| MTD - BRKR | 75% Closely correlated | -0.86% | ||
| WAT - BRKR | 68% Closely correlated | -1.17% | ||
| RVTY - BRKR | 68% Closely correlated | -1.83% | ||
| TMO - BRKR | 66% Loosely correlated | -1.33% | ||
More | ||||